Joel Sendek to Join Stifel Nicolaus' Healthcare Equity Research Team
November 28, 2011 16:13 ET
Joel Sendek to Join Stifel Nicolaus' Healthcare Equity Research Team
ST. LOUIS, MO--(Marketwire - Nov 28, 2011) - Stifel Financial Corp. (
"We are very pleased that Joel will be joining the Stifel healthcare research team," stated Hugh Warns, Director of Research at Stifel Nicolaus. "Joel is a proven professional who brings a unique combination of leadership, experience and expertise to our industry-leading healthcare research capabilities. Bringing Joel onto the team furthers our unwavering commitment to research."
Mr. Sendek will bring over 20 years of experience, including the past eleven with Lazard Capital Markets, where he established the healthcare equity research effort. He is widely recognized in the investment community and the corporate world for his broad biotechnology expertise and proprietary insight, including a previous #1 ranking for "Stock Picking" in The Wall Street Journal's Best on the Street Survey. Prior to his career in equity research, Mr. Sendek spent five years as a Senior Director in Corporate Development at Progenics Pharmaceuticals and three years as an investment banking analyst at Goldman Sachs. He is a graduate of Rice University, where he received a B.A. in Biochemistry. Mr. Sendek will be based in the firm's New York office and will join Stifel in January 2012.
Company Information
Stifel Financial Corp. (